Science & Research

Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory depression

Diogo R. Lara, Luisa W. Bisol, Luciano R. Munari International Journal of Neuropsychopharmacology, Volume 16, Issue 9, October 2013, Pages 2111–2117, https://doi.org/10.1017/S1461145713000485 Abstract Intravenous ketamine (0.5 mg/kg) produces robust, rapid and long-lasting antidepressant effects, but is unpractical. Sublingual administration of ketamine renders better bioavailability (∼30%) and less conversion to norketamine than oral administration. We evaluated …

Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory depression Read More »

Ketamine—50 years in use: A study

Samuel Kohtala1,2,3 1Laboratory of Neurotherapeutics, Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P. O. Box 56, 00014 Helsinki, Finland 2SleepWell Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland 3Feil Family Brain and Mind Research Institute, Department of Psychiatry, Weill Cornell Medicine, New York, NY USA Samuel …

Ketamine—50 years in use: A study Read More »

Low Dose Ketamine Infusion for Posttraumatic Stress Disorder and Chronic Pain

Alisher R. Dadabayev,1,2 Sonalee A. Joshi,3 Mariam H. Reda,4 Tamar Lake,1,2 Mark S. Hausman,1,2 Edward Domino,5 and Israel Liberzon6 1Department of Anesthesiology, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA 2Department of Anesthesiology, University of Michigan Health System, Ann Arbor, MI, USA 3Department of Psychology, The University of Michigan, Ann Arbor, MI, USA 4Department …

Low Dose Ketamine Infusion for Posttraumatic Stress Disorder and Chronic Pain Read More »

Ketamine for the acute treatment of severe suicidal ideation

Mocrane Abbar, chief of clinical department 1,  Christophe Demattei, statistician 2,  Wissam El-Hage, chief of clinical department 3,  Pierre-Michel Llorca, chief of clinical department 4,  Ludovic Samalin, assistant professor of psychiatry 4,  Pierre Demaricourt, chief of clinical department 5,  Raphael Gaillard, chief of clinical department 5,  Philippe Courtet, chief of clinical department 6 7,  Guillaume …

Ketamine for the acute treatment of severe suicidal ideation Read More »

Ketamine for Depression, A Clinical Summary

Chittaranjan Andrade 1 1 Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore, India. candrade@psychiatrist.com.   Chittaranjan Andrade, MD Ketamine is an anesthetic drug. It is used in subanesthetic doses to treat pain, to effect sedation, or to ameliorate depression in various contexts. Ketamine as an antidepressant is most commonly administered as an intravenous infusion, …

Ketamine for Depression, A Clinical Summary Read More »

How the glutathione cycle shapes synaptic glutamate activity

    Thomas W Sedlak 1, Bindu D Paul 2, Gregory M Parker 3, Lynda D Hester 2, Adele M Snowman 2, Yu Taniguchi 3, Atsushi Kamiya 3, Solomon H Snyder 1 2 4, Akira Sawa 3 Affiliations expand PMID: 30692251 PMCID: PMC6377501 DOI: 10.1073/pnas.1817885116 Free PMC article  Abstract Glutamate is the most abundant excitatory neurotransmitter, present at the bulk of cortical synapses, and participating in many physiologic and pathologic processes ranging from learning …

How the glutathione cycle shapes synaptic glutamate activity Read More »

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series

Hewa Artin, Sean Bentley, Eamonn Mehaffey, Fred X. Liu, Kevin Sojourner, Andrew W. Bismark, David Printz, Ellen E. Lee, Brian Martis, Sharon De Peralta, Dewleen G. Baker, Jyoti Mishra, Dhakshin Ramanathan Published 6 May 2022 | https://doi.org/10.1016/j.eclinm.2022.101439 Abstract Background (S)-ketamine is a glutamatergic drug with potent and rapid acting effects for the treatment of depression. …

Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series Read More »

Ketamine treatment for refractory anxiety: A systematic review

Jamie L. Tully, Amelia D. Dahlén, Connor J. Haggarty, Helgi B. Schiöth, Samantha Brooks First published: 04 May 2022 | https://doi.org/10.1111/bcp.15374 Abstract There is a growing interest in the psychiatric properties of the dissociative anaesthetic ketamine, as single doses have been shown to have fast-acting mood-enhancing and anxiolytic effects, which persist for up to a …

Ketamine treatment for refractory anxiety: A systematic review Read More »

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder

C. Sophia Albott, Kelvin O. Lim, Christopher Erbes, Paul Thuras, Joseph Wels, Susanna J.Tye, Paulo R. Shiroma Published 14 April 2022 | https://doi.org/10.1016/j.jad.2022.04.066 Abstract Background The glutamate N-methyl-d-aspartate (NMDA) receptor antagonist ketamine rapidly ameliorates posttraumatic stress disorder (PTSD) and depression symptoms in individuals with comorbid PTSD and major depressive disorder (MDD). However, concerns over ketamine’s …

Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder Read More »